Aclaris Therapeutics, Inc.
ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS

Last updated:

Abstract:

The present disclosure relates to oral compositions of Compound I or a derivative thereof. Methods of use for treating an inflammatory condition are also disclosed.

Status:
Application
Type:

Utility

Filling date:

26 Mar 2021

Issue date:

4 Nov 2021